From MarketBeat:

Enliven Therapeutics, Inc. COO Anish Patel sold 983 shares of the company’s stock at $15.03 per share on December 22nd. Patel also sold 102 shares on December 26th at an average price of $15.01. The company has a market capitalization of $607.62 million and shares trade on NASDAQ under the symbol ELVN. Enliven posted quarterly earnings results on November 9th, reporting a loss of ($0.51) per share, lower than the consensus estimate. Analysts project Enliven to post a loss of -2.24 earnings per share for the current year. Institutional investors and hedge funds have made changes to their positions in Enliven Therapeutics, with institutional inflows and outflows affecting the stock.

Enliven Therapeutics focuses on the discovery and development of small molecule inhibitors to treat cancer. The company is currently evaluating ELVN-001 in a Phase 1 clinical trial for patients with chronic myeloid leukemia and is also running a Phase 1 clinical trial for ELVN-002 for adults with solid tumors with HER2 alterations. The news report was generated by narrative science technology and financial data from MarketBeat for the fastest and most accurate reporting.

MarketBeat provides insights from Wall Street’s top-rated analysts but has found five stocks that these analysts are more confident about compared to Enliven Therapeutics. Additionally, MarketBeat has released a list of 10 cheap stocks that may be undervalued.



Read more: Anish Patel Sells 983 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock